Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SIEMENS HEALTHINEERS AG

(SHL)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Siemens Healthineers : Corporate Governance Statement in accordance with § 289f and § 315d German Commercial Code (HGB) – Nov 25, 2021 (pdf) 29.68 MB

11/25/2021 | 02:10am EST

Corporate Governance Statement

Documents pursuant to § 289f (2) and § 315d German Commercial Code (HGB)

The documents referred to in the Corporate Governance statement pursuant to § 289f and § 315d of the German commercial code (HGB) can be found here. Each of the documents is as of September 30, 2021.

  • Two-tier board
  • German Corporate Governance Code
  • Business Conduct Guidelines
  • Compensation Report including auditor's report
  • Compensation system for the Managing Board
  • Bylaws for the Managing Board
  • Compensation system for the Supervisory Board
  • Bylaws of the Supervisory Board

As of 30.09.2021

Siemens Healthineers Annual Report 2021

Additional information  -Corporate governance statement

C.4  Corporate governance statement

Publicly listed stock corporations are required to prepare and publish an annual statement on corporate governance, with the parent companies having to do so on behalf of their group companies. This statement combines the corporate governance statement of ­Siemens Healthineers AG­ in accordance with Section 289 f of the German Commercial Code (Handelsgesetzbuch,­ HGB) and the Group corporate governance statement in accordance with Section 315 d of the German Commercial Code. The Corporate Governance statement is an integral part of the combined management report. Pursuant to Section 317 (2) sentence 6 of the German Commercial Code, the independent auditors' review of the disclosures made within the scope of Sections 289 f and 315 d of the German Commercial Code is to be limited to ascertaining whether the disclosures were made.

According to Principle 22 of the German Corporate Governance Code (Deutscher Corporate Governance Kodex, hereinafter "GCGC"), this combined corporate governance statement for ­Siemens ­Healthineers AG and the Group is a key instrument of corporate governance reporting.

C.4.1 Two-tier board

Siemens ­ Healthineers AG­is subject to the regulations of German stock corporation law. It therefore has a two-tier board structure, with a Managing Board and Supervisory Board that are separate in terms of both functions and personnel. Both governing bodies cooperate closely in the interests of the Company.

In addition to the applicable statutory provisions, the GCGC provides the de jure and de facto framework for managing and monitoring the Company. The goal of the GCGC is to make ­Germany's two-tier system of corporate governance transparent and comprehensible.

C.4.1.1  Composition and working methods of the Managing Board

As the Company's top management body, the Managing Board is committed to serving the Company's interests and achieving sustainable growth in the Company's value. The members of the Managing Board are jointly responsible for the entire management of the Company and decide on the basic issues of business policy and corporate strategy, as well as on the Company's annual and multiyear plans.

The Managing Board is responsible for the preparation of the quarterly statements and the half-yearfinancial report, the annual financial statements of ­Siemens ­Healthineers AG, the consolidated financial statements of the Group, and the combined management report of Siemens ­Healthineers AG­ and the Group. In addition, the Managing Board ensures that the Company adheres to the requirements of legislation, government regulations, and internal Company guidelines, and works to ensure that Group companies comply with these provisions and guidelines. The Managing Board has established a comprehensive compliance management system. Details are available on the website at  www.siemens-healthineers.com/company/ compliance.

The Managing Board informs the Supervisory Board regularly, comprehensively, and without delay on all issues of importance to the Company with regard to strategy, planning, business development, the risk situation, risk management, and com- pliance. When filling managerial positions in the Company, the Managing Board takes diversity into consideration and, in par- ticular, aims for appropriate gender representation.

Information on the areas of responsibility and the curricula ­vitae of the members of the Managing Board are available on the Company's website at  www.siemens-healthineers.com/ company/management.

You will find further information about the Managing Board on our website:

investor-relations/corporate-governance/managing-board-compensation .

  • Compensation Report 2021 including the auditor's report in accordance with Section 162 of the German Stock Corporation Act is available at www.siemens-healthineers.com/inves-

tor-relations/corporate-governance.

  • Bylaws of the Managing Board are available at www.sie-

mens-healthineers.com/investor-relations/corporate-governance/ bylaws.

105

Siemens Healthineers Annual Report 2021

Additional information  -Corporate governance statement

Members of the Managing Board and positions held by Managing Board members

In fiscal year 2021 the Managing Board comprised the following members:

Memberships in supervisory boards whose establishment

is required by law or in comparable domestic or foreign

controlling bodies of business enterprises

External positions

Group company positions

Name

Year of birth

First appointed

Term expires

(as of September 30, 2021)

(as of September 30, 2021)

Dr. Bernhard Montag

1969

2018

2026

None

None

Chief Executive Officer

Darleen Caron

1964

2021

2024

None

None

(since February 1, 2021)

Dr. Jochen Schmitz

1966

2018

2026

German positions:

None

• Universitätsklinikum

Augsburg

Dr. Christoph Zindel

1961

2019

2022

None

None

C.4.1.2  Composition and working methods of the Supervisory Board

The Supervisory Board oversees and advises the Managing Board in its management of the Company's business. At regular inter- vals, the Supervisory Board discusses business development, planning, strategy, and strategy implementation. It reviews the annual financial statements of Siemens ­Healthineers AG,­ the consolidated financial statements, and the combined management report, as well as the proposal for the appropriation of net income. It approves the annual financial statements of ­Siemens ­Healthineers AG as well as the consolidated financial statements, based on the results of the pre-examination conducted by the Audit Committee and taking into account the reports of the independent auditors. The Supervisory Board decides on the Managing Board's proposal for the appropriation of net income and the Report of the Supervisory Board to the Annual Shareholders' Meeting. In addition, the Supervisory Board or the Audit Committee, as appropriate, concerns itself with monitoring the Company's compliance with the requirements of legislation, government regulations, and internal Company guidelines. The Supervisory Board also appoints the members of the Managing Board and determines each member's business responsibilities. Important Managing Board decisions - such as those regarding major acquisitions, divestments, investments in property, plant, and equipment, or financial measures­ - are subject to Supervisory Board approval, unless the bylaws for the Supervisory Board specify that such authority is delegated to one of the Supervisory Board committees. The bylaws of the Supervisory Board set out not only its tasks and responsibili- ties, but also the procedure for holding meetings and adopting resolutions.

In the bylaws for the Managing Board, the Supervisory Board has established the rules that govern the Managing Board's work.

The activities of the Supervisory Board and its committees during the reporting period are discussed in the Report of the Supervisory Board  C.3  Report of the Supervisory Board.

The curricula vitae of the members of the Supervisory Board are available on the Company's website at  www.siemens-health-

ineers.com/investor-relations/supervisory-board.

You will find further information about the Supervisory Board on our website:

rate-governance/supervisory-board-compensation.

lations/corporate-governance.

  • Bylaws of the Supervisory Board are available at www.sie-

mens-healthineers.com/investor-relations/corporate-governance/ bylaws.

The Supervisory Board of ­Siemens Healthineers AG­ comprises ten members. It is composed entirely of shareholder represen- tatives. The terms of office of the members of the Supervisory Board who were appointed in 2018 will expire at the conclusion of the Annual Shareholders' Meeting in 2023. The terms of office of the members who were appointed in 2020 (Dr. Roland­ Busch) and 2021 (Mr. Peer M. Schatz) will expire at the conclusion of the Annual Shareholders' Meeting in 2025 and 2026, respectively.

106

Siemens Healthineers Annual Report 2021

Additional information  -Corporate governance statement

Members of the Supervisory Board and positions held by Supervisory Board members

In fiscal year 2021 the Supervisory Board comprised the following members:

Name

Occupation

Year of birth

Member since

Prof. Dr. Ralf P. Thomas

Member of the

1961

2018

Chairman

Managing Board of

Siemens Aktiengesellschaft

(Chief Financial Officer)

Dr. Norbert Gaus

Executive Vice President

1961

2018

Deputy Chairman

Corporate Technology of

Siemens Aktiengesellschaft

Dr. Roland Busch

President and

1964

2020

Chief Executive Officer of

Siemens Aktiengesellschaft

Dr. Marion Helmes

Supervisory board member

1965

2018

Dr. Andreas C. Hoffmann

General Counsel of

1964

2018

Siemens Aktiengesellschaft

Dr. Philipp Rösler

Supervisory board member

1973

2018

Peer M. Schatz

Managing Director of

1965

2021

(since March 23, 2021)

PS Captial Management

GmbH

Dr. Nathalie von Siemens­

Supervisory board member

1971

2018

Dr. Gregory Sorensen

Founder and CEO of

1962

2018

DeepHealth, Inc. (artificial

intelligence division of

RadNet, Inc.) and

Executive Chairman of IMRIS

(Deerfield Imaging, Inc.)

Karl-Heinz Streibich

President of acatech -

1952

2018

Deutsche Akademie der

Technikwissenschaften

Memberships in supervisory boards whose establishment is required by law or in comparable domestic or foreign controlling bodies of business enterprises

(as of September 30, 2021)

German positions:

• Siemens­ Energy AG

• Siemens­ Energy Management GmbH

• ­Siemens ­Healthcare GmbH (Chair)

Positions outside Germany:

• Siemens­ Proprietary Ltd., South Africa

German positions:

• Siemens ­ Healthcare­ GmbH

German positions:

• Siemens­ Mobility GmbH (Chair)

German positions:

  • ProSiebenSat.1 Media SE (Deputy Chair)
    Positions outside Germany:
  • British American Tobacco p. l. c., United Kingdom
  • Heineken N. V., The Netherlands

German positions:

• Siemens ­ Healthcare­ GmbH

Positions outside Germany:

• Siemens Ltd­., China

German positions:

• Brainloop AG

Positions outside Germany:

  • Fortum Corporation, Finland
  • Loc Troi Group, Vietnam

German positions:

  • Resolve BioSciences GmbH (Chair)
    Positions outside Germany:
  • CENTOGENE N. V., The Netherlands (Chair)

German positions:

  • Messer Group GmbH
  • Siemens­ Aktiengesellschaft
  • Siemens ­ Healthcare­ GmbH
  • TÜV SÜD AG

Positions outside Germany:

• EssilorLuxottica S. A., France

German positions:

  • Fresenius Medical Care AG & Co. KGaA
  • Fresenius Medical Care Management AG
    Positions outside Germany:
  • DFP Healthcare Acquisitions Corp., USA
  • Invicro, LLC, USA

German positions:

  • Deutsche Telekom AG
  • Münchener Rückversicherungs-Gesellschaft AG
  • Software AG (Chair)

107

Siemens Healthineers Annual Report 2021

Additional information  -Corporate governance statement

Supervisory Board committees

The Supervisory Board has four committees, whose duties, re- sponsibilities, and procedures fulfill the requirements of the German Stock Corporation Act and the GCGC. The chairpersons of these committees provide the Supervisory Board with regular reports on the committees' activities.

Committees

Members

Chairman's

Prof. Dr. Ralf P. Thomas (Chair)

Committee

• Dr. Norbert Gaus

• Dr. Andreas C. Hoffmann

Audit

Dr. Marion Helmes (Chair)

Committee

• Dr. Andreas C. Hoffmann

• Prof. Dr. Ralf P. Thomas

Innovation and Finance

Prof. Dr. Ralf P. Thomas (Chair)

Committee

• Dr. Roland Busch

• Dr. Norbert Gaus

• Peer M. Schatz

• Dr. Gregory Sorensen

• Karl-Heinz Streibich

Related-Party Transactions

Dr. Marion Helmes (Chair)

Committee

• Dr. Andreas C. Hoffmann

• Karl-Heinz Streibich

The Chairman's Committee coordinates the work of the Supervisory Board and prepares the meetings of the Supervisory Board. It prepares the self-assessment of the Supervisory Board's work and monitors the implementation of the resolutions adopted by the Supervisory Board or its committees. It makes proposals regarding the appointment and dismissal of Managing Board members and handles contracts with members of the Managing Board. When making recommendations for first-time appointments, it takes into account that the term of these appointments should not, as a rule, exceed three years. In preparing recommendations on the appointment of Managing Board members, the Chairman's Committee takes into account the candidates' professional qualifications, international experience and leadership qualities, the age limit specified for Managing Board members, the long-range plans for succession, and diver- sity. It also takes into account the targets that the Supervisory Board has specified for the share of women on the Managing Board. It decides on approving contracts and transactions with members of the Managing Board and their related parties, whether individuals or entities. The Chairman's Committee submits proposals to the Supervisory Board for setting the compensation of the individual Managing Board members. The Chairman's Committee prepares resolutions of the Supervisory Board regarding the systems of Managing Board and Super­ visory Board compensation, including the regular review of those systems. The Chairman's Committee furthermore has the task of providing the Supervisory Board with recommendations of suitable candidates for the board to nominate for election by the Annual Shareholders' Meeting as new members of the Supervisory Board. It therefore has the tasks of a nomination committee. In preparing these recommendations, the targets defined by the Supervisory Board for its composition are to be given due consideration, along with the proposed candidates' required knowledge, abilities, and professional experience. Fulfillment of the profile of required skills and expertise is also to be aimed for. The Chairman's Committee has furthermore

been authorized by the Supervisory Board to decide on the approval of Managing Board proposals regarding appointment or dismissal of persons in certain management positions at the first level below the Managing Board, and the main principles of the compensation and incentivization system for employees.

In fiscal year 2021, the Chairman's Committee had the following members: Prof. Dr. Ralf P. Thomas (Chairman), Dr. Norbert Gaus and Dr. Andreas C. Hoffmann.

The Audit Committee oversees, in particular, accounting and the accounting process. It conducts a pre-examination of the annual

financial statements of Siemens ­ Healthineers AG,­the consolidated financial statements, and the combined management report, as well as the report on relationships with affiliated com- panies. On the basis of the independent auditors' report on their audit of the financial statements, the Audit Committee makes, after its own pre-examination, recommendations regarding the Supervisory Board's approval of the annual financial statements of ­Siemens ­Healthineers AG and the consolidated financial statements. The Audit Committee discusses the quarterly statements and half-year financial report with the Managing Board and the independent auditors and deals with the audi- tors' reports on the review of the Group's half-year consolidated financial statements and interim management report. It concerns itself with questions of risk management and oversees the suitability and effectiveness of the systems for internal control, risk management, and internal auditing. The Audit Committee receives regular reports from the internal audit department. It prepares the Supervisory Board's recommendation to the Annual Shareholders' Meeting concerning the election of the independent auditors and submits the corresponding proposal to the Supervisory Board. Once the Annual Shareholders' Meeting has made a resolution, the Audit Committee awards the audit contract to the independent auditors and monitors the independent audit of the financial statements, particularly the selection, independence, and qualification of the auditors. It evaluates the quality of the audit and the work of the independent auditors, including the additional services they provide. In this regard, the committee complies with the applicable legal requirements, including in particular the requirements under the EU Audit Regulation (Regulation (EU) No. 537 / 2014 of the European Parliament and of the Council of 16 April 2014 on specific requirements of statutory audits of public-interest entities and repealing Commission Decision 2005 / 909 / EC). The Audit Committee furthermore concerns itself with monitoring compliance, and with nonfinancial reporting and exemptions from such reporting.

In fiscal year 2021, the Audit Committee had the following members: Dr. Marion Helmes (Chairwoman since September 28, 2021), Dr. Andreas C. Hoffmann (Chairman until September 27, 2021) and Prof. Dr. Ralf P. Thomas.

108

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Siemens Healthineers AG published this content on 25 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 25 November 2021 07:09:06 UTC.


© Publicnow 2021
All news about SIEMENS HEALTHINEERS AG
12/07Biotechnology firm Freenome raises $300 million in fresh funding
RE
12/06SIEMENS HEALTHINEERS AG : Release of a capital market information
EQ
12/06Siemens AGMunich; Supervisory Board renews the term of office of Ralf Thomas, Managing ..
AQ
12/03Siemens AG - Supervisory Board renews the term of office of Ralf Thomas, Managing Board..
AQ
12/02Siemens Renews CFO's Term Of Office
MT
12/02Siemens Renews Term for CFO Ralf Thomas
DJ
12/02Atos and Siemens to support Morocco in the smart management of its power grid
AQ
12/01Freenome Partners with Siemens Healthineers for Breast Cancer Research
CI
11/29SIEMENS HEALTHINEERS AG : Release of a capital market information
EQ
11/26Siemens AG - Halfway point of 2023 research period for Aspern Smart City Research
AQ
More news
Analyst Recommendations on SIEMENS HEALTHINEERS AG
More recommendations
Financials
Sales 2022 19 879 M 22 548 M 22 548 M
Net income 2022 1 938 M 2 199 M 2 199 M
Net Debt 2022 11 991 M 13 601 M 13 601 M
P/E ratio 2022 38,2x
Yield 2022 1,41%
Capitalization 74 956 M 84 955 M 85 018 M
EV / Sales 2022 4,37x
EV / Sales 2023 4,03x
Nbr of Employees 66 000
Free-Float 24,2%
Chart SIEMENS HEALTHINEERS AG
Duration : Period :
Siemens Healthineers AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SIEMENS HEALTHINEERS AG
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Last Close Price 66,82 €
Average target price 67,97 €
Spread / Average Target 1,73%
EPS Revisions
Managers and Directors
Bernhard Montag Chief Executive Officer
Jochen Schmitz Chief Financial Officer
Ralf Peter Thomas Chairman-Supervisory Board
Thorsten Opderbeck Head-Technology, Trade & Regional Media
A. Gregory Sorensen Member-Supervisory Board
Sector and Competitors